Wearables have the potential to demonstrate the value of drug products through more reliable outcomes data
The use of digital technologies is increasing in all areas of health care, from the use of electronic patient records, incorporation of digital technologies into patient care pathways, to the use of wearables to assess outcomes and/or deliver health care interventions in their own right.
Wearables have the potential for assessing outcomes in novel ways, in real time and over extended periods of time. They also have potential for demonstrating the value of drug products by generating more reliable outcomes data. For example, in the context of outcomes based agreements (OBAs) and payer re-evaluation of drug products, both require the generation of real world data to support reimbursement. The ability of payers and manufacturers to accurately track outcomes has been commonly cited as a barrier to adoption of outcomes based agreements. Wearables may offer a solution to both the efficiency and accuracy of tracking outcomes, facilitating wider implementation of OBAs and more effective drug product re-evaluation. There are also a number of challenges facing wearable and drug manufacturers, in particular the evolving payer evidence requirements for accepting digital outcomes generated from wearables.
In this webinar, we will look at:
- The issues facing the industry in the application of digital health technologies to capture real world data cost-effectively to support reimbursement strategies
- The measures payers are taking to evaluate wearables and the data they generate
- Payer perceptions of the value of wearables, the evolving digital environment and their evidence needs for adoption of these technologies, based on direct discussions with US and EU payers
We will also share case studies to demonstrate the value wearables can deliver when supporting drug product reimbursement.
Join us to learn:
- Challenges in use of RWE in outcome-based agreements and proof of product value post launch
- Payer perspective on the value of wearables and digital health in product reimbursement
- Examples of therapy areas where digital devices are currently aiding clinical patient management
- Possible solutions to challenges raised by payers in use of wearables and digital health tools to help secure drug product reimbursement.
Bob Swann, MBA
Senior Principal, Pricing, Market Access and Reimbursement
Bob has over 25 years of experience in market access consultancy and industry. At ICON is a project lead for global pricing and market access client engagements. His experience includes all access including pricing, reimbursement, HTA support, multiple therapy areas and product types including ATMPs.
Marie McCarthy, MSc, MBA
Senior Director Product Innovation
Marie has over 20 years’ experience working in the area of medical devices and in-vitro diagnostics. Her focus for that last 11 years has been the use of wearables and sensors to generate digital endpoints in clinical trials. She has been with ICON for five years working as a subject matter expert in the deployment and use of wearables and sensors in clinical trials.
Gary Owens, MD
Vice President, Pricing, Market Access, Reimbursement
Gary has over 25 years of health plan experience in medical and pharmacy management at senior executive level, managing medical services for a large regional health plan, and pharmacy benefit and pharmacy operations for 3.0 million members. In his role at ICON, he is focused on the evaluation of new and emerging technology and pharmacy issues including formulary management, health economics and reimbursement issues.
Benjamin Schatzman, Pharm.D
Pricing, Market Access and Reimbursement
Dr. Benjamin Schatzman has over 21 years of managed care pharmacy experience, including PBM and Managed Care. His expertise includes formulary management, medical policy, payer access, health plan pharmacy operations, regulatory and governmental affairs work pertaining to pharmacy, PBM and specialty pharmacy oversight, and government-sponsored health plans including Medicaid, Medicare, and Health Insurance Exchange.
Will Maier, MPH, PhD
Chief Science Officer & Head, Rare Diseases
William has over 30 years of experience with pharmaceutical companies in Europe, Canada, the United States and Asia. At ICON he works with pharmaceutical companies to provide regulatory, strategic and scientific guidance on medical treatment development and commercialisation. He is a member of the EMEA’s European Network of Centres for Pharmacoepidemiology and Pharmacovigilance.
This program will be beneficial for pharmaceutical, medical device, and biotechnology professionals working in the following areas:
- Market access
- Pricing and reimbursement
- Clinical development
- Patient outcomes
- Real world evidence
- Health economics